Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
2.3
2.4
Journals
Veterinary Sciences
Special Issues
Current Advances in Veterinary Oncology
share announcement

Current Advances in Veterinary Oncology

A special issue of Veterinary Sciences (ISSN 2306-7381).

Deadline for manuscript submissions: closed (20 February 2023) | Viewed by 9812

Special Issue Editors

Dr. Lucia Minoli

E-Mail Website
Guest Editor
Dipartimento di Scienze Veterinarie, Università degli Studi di Torino, Largo Braccini 2, 10095 Grugliasco (TO), Italy
Interests: veterinary pathology; comparative pathology; oncology; lymphoma
Prof. Dr. Luca Aresu

E-Mail Website
Co-Guest Editor
Dipartimento di Scienze Veterinarie, Università degli Studi di Torino, Largo Braccini 2, 10095 Grugliasco (TO), Italy
Interests: veterinary oncology; veterinary anatomic pathology

Special Issue Information

Dear Colleagues,

Cancer in pets is an increasing cause of morbidity and mortality worldwide. Driven by the development of novel techniques and the deepening of knowledge pertaining to tumor biology, veterinary oncology has witnessed substantial advances in the last decade. Genetic and transcriptomic technologies have generated an enormous amount of data, expanding our understanding of canine and feline cancer biology. Novel targets, including hypoxia, angiogenesis, apoptosis, DNA repair, and growth factors and their receptors, have been identified; however, currently, very few have been translated into clinically applicable therapeutics.

Within this context, the introduction of anti-tumor vaccines, in addition to the standard of care, demonstrated the relevant role of anti-tumor immunity and the possibility of exploiting the patient’s own immune system to develop new therapeutic strategies. In addition, the integration of morphological features with the molecular and genomic characterization of tumors and clinicopathological data allowed the pathologic basis of cancer in animals to be elucidated, in order to identify druggable targets, develop specific treatments tailored to the tumor type, as well as to better anticipate the prognosis and predict the response to treatment.

This Special Issue of Veterinary Science is focused on the current knowledge and recent advances in veterinary oncology. We encourage submissions of original research articles and reviews that focus on various aspects of veterinary oncology, including tumor pathology, cancer genetics and epigenetics, diagnostic and prognostic tools, and novel therapeutic approaches.

Dr. Lucia Minoli
Prof. Dr. Luca Aresu
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Veterinary Sciences is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • veterinary oncology
  • canine
  • feline
  • pathology
  • diagnosis
  • prognostic markers
  • therapy

Published Papers (4 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

15 pages, 11746 KiB  
Article
Gadolinium Neutron Capture Therapy for Cats and Dogs with Spontaneous Tumors Using Gd-DTPA
by Vladimir Kanygin, Alexander Zaboronok, Aleksandr Kichigin, Elena Petrova, Tatyana Guselnikova, Andrey Kozlov, Dmitriy Lukichev, Bryan J. Mathis and Sergey Taskaev
Vet. Sci. 2023, 10(4), 274; https://doi.org/10.3390/vetsci10040274 - 4 Apr 2023
Cited by 1 | Viewed by 1978
Abstract
We conducted a clinical veterinary study on neutron capture therapy (NCT) at a neutron-producing accelerator with seven incurable pets with spontaneous tumors and gadolinium as a neutron capture agent (gadolinium neutron capture therapy, or GdNCT). Gadolinium-containing dimeglumine gadopentetate, or Gd-DTPA (Magnevist®, [...] Read more.
We conducted a clinical veterinary study on neutron capture therapy (NCT) at a neutron-producing accelerator with seven incurable pets with spontaneous tumors and gadolinium as a neutron capture agent (gadolinium neutron capture therapy, or GdNCT). Gadolinium-containing dimeglumine gadopentetate, or Gd-DTPA (Magnevist®, 0.6 mL/kg b.w.), was used. We observed mild and reversible toxicity related to the treatment. However, no significant tumor regression in response to the treatment was observed. In most cases, there was continued tumor growth. Overall clinical improvement after treatment was only temporary. The use of Gd-DTPA for NCT had no significant effects on the life expectancy and quality of life of animals with spontaneous tumors. Further experiments using more advanced gadolinium compounds are needed to improve the effect of GdNCT so that it can become an alternative to boron neutron capture therapy. Such studies are also necessary for further NCT implementation in clinical practice as well as in veterinary medicine. Full article
(This article belongs to the Special Issue Current Advances in Veterinary Oncology)
►▼ Show Figures

Figure 1

9 pages, 921 KiB  
Article
Mutations in Exons 8 and 11 of c-kit Gene in Canine Subcutaneous Mast Cell Tumors and Their Association with Cell Proliferation
by Polly Chen, Laura Marconato, Silvia Sabattini and Matti Kiupel
Vet. Sci. 2022, 9(9), 493; https://doi.org/10.3390/vetsci9090493 - 10 Sep 2022
Cited by 6 | Viewed by 2207
Abstract
The prognostic significance of internal tandem duplication (ITD) mutations in exons 8 and 11 of c-kit has been well-described for canine cutaneous mast cell tumors (MCTs), but c-kit mutations have rarely been reported in subcutaneous MCTs. The objective of this study was to [...] Read more.
The prognostic significance of internal tandem duplication (ITD) mutations in exons 8 and 11 of c-kit has been well-described for canine cutaneous mast cell tumors (MCTs), but c-kit mutations have rarely been reported in subcutaneous MCTs. The objective of this study was to identify the prevalence of ITD mutations in exons 8 and 11 of c-kit in canine subcutaneous MCTs and to investigate its association with histologic grade, KIT pattern, and proliferation markers. ITD mutations in exons 8 and 11 of c-kit, mitotic count, Ki67 index, AgNOR number, Ki67xAgNOR score, KIT pattern, and histologic grade (two-tier system) were retrospectively recorded for 216 dogs with subcutaneous MCTs. ITD mutations in exons 8 and 11 of c-kit were detected in 23 (10.6%) and 12 (5.56%) subcutaneous MCTs, respectively. Exon 11 mutations were significantly associated with Kiupel high grade (p < 0.001) and increased mitotic count (p < 0.001) compared to subcutaneous MCTs with no mutations in exons 8 or 11 (p = 0.002) or subcutaneous MCTs with a mutation in exon 8 (p = 0.001). There was no significant association of either c-kit mutation with KIT patterns or proliferation activity. This study identified a higher prevalence of ITD mutations in exons 8 and 11 of c-kit in subcutaneous MCTs than previously reported. Like their cutaneous counterpart, subcutaneous MCTs with exon 11 mutations were more likely to be histologically high grade and have a higher mitotic count, whereas such associations were not observed in subcutaneous MCTs with exon 8 mutations. Full article
(This article belongs to the Special Issue Current Advances in Veterinary Oncology)
►▼ Show Figures

Figure 1

10 pages, 1421 KiB  
Article
IL-1R8 Downregulation and Concomitant TLR7 and TLR9 Upregulation Are Related to the Pathogenesis of Canine Diffuse Large B-Cell Lymphoma
by Federica Riva, Joel Filipe, Antonella Fanelli, Laura Marconato, Alessia Inglesi, Eugenio Scanziani, Sabina Soldati, Luca Licenziato, Stefano Comazzi, Lucia Minoli and Luca Aresu
Vet. Sci. 2022, 9(5), 209; https://doi.org/10.3390/vetsci9050209 - 25 Apr 2022
Cited by 1 | Viewed by 2537
Abstract
Diffuse large B-cell lymphoma (DLBCL) is the most common hematological malignancy in humans and dogs. Several studies disclosed some similarities between the two species, including the constitutive activation of the NF-κB pathway as a fundamental underlying pathogenetic mechanism. In humans, the downregulation of [...] Read more.
Diffuse large B-cell lymphoma (DLBCL) is the most common hematological malignancy in humans and dogs. Several studies disclosed some similarities between the two species, including the constitutive activation of the NF-κB pathway as a fundamental underlying pathogenetic mechanism. In humans, the downregulation of IL-1R8 is implicated in DLBCL development, but its role in dogs has not been explored so far. To gain insight into the pathogenesis of this tumor in dogs, we evaluated the mRNA and protein expression of IL-1R8 in 12 control lymph nodes obtained from dogs not bearing tumors and from 50 dogs with DLBCL. Moreover, we analyzed through qRT-PCR the expression of TLR7, TLR9, MYC, and p52 genes that are known to be involved in the IL-1R8 regulatory network. IL-1R8 and p52 were downregulated in DLBCLs compared to control lymph nodes (p < 0.001), while a higher expression of TLR7, TLR9, and MYC was observed in DLBCLs (p < 0.01). Immunohistochemistry confirmed the gene expression results, revealing a significantly lower IL-1R8 staining score in DLBCLs compared to control lymph nodes (p < 0.0001). Taken together, these results suggest that IL-1R8 downregulation may represent one of the mechanisms driving DLBCL pathogenesis in dogs, mainly through the dysregulation of the Toll-like/interleukin receptors signaling cascade and the aberrant activation of the classical NF-κB pathway. Full article
(This article belongs to the Special Issue Current Advances in Veterinary Oncology)
►▼ Show Figures

Figure 1

Review

Jump to: Research

30 pages, 558 KiB  
Review
An Overview of Epithelial-to-Mesenchymal Transition and Mesenchymal-to-Epithelial Transition in Canine Tumors: How Far Have We Come?
by Federico Armando, Federico Mazzola, Luca Ferrari and Attilio Corradi
Vet. Sci. 2023, 10(1), 19; https://doi.org/10.3390/vetsci10010019 - 28 Dec 2022
Cited by 4 | Viewed by 1978
Abstract
Historically, pre-clinical and clinical studies in human medicine have provided new insights, pushing forward the contemporary knowledge. The new results represented a motivation for investigators in specific fields of veterinary medicine, who addressed the same research topics from different perspectives in studies based [...] Read more.
Historically, pre-clinical and clinical studies in human medicine have provided new insights, pushing forward the contemporary knowledge. The new results represented a motivation for investigators in specific fields of veterinary medicine, who addressed the same research topics from different perspectives in studies based on experimental and spontaneous animal disease models. The study of different pheno-genotypic contexts contributes to the confirmation of translational models of pathologic mechanisms. This review provides an overview of EMT and MET processes in both human and canine species. While human medicine rapidly advances, having a large amount of information available, veterinary medicine is not at the same level. This situation should provide motivation for the veterinary medicine research field, to apply the knowledge on humans to research in pets. By merging the knowledge of these two disciplines, better and faster results can be achieved, thus improving human and canine health. Full article
(This article belongs to the Special Issue Current Advances in Veterinary Oncology)
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-4
Back to TopTop